S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Look at Honeywell for a Steady and Diversified Stock
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Look at Honeywell for a Steady and Diversified Stock
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Look at Honeywell for a Steady and Diversified Stock
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Why Invest in High-Yield Dividend Stocks?
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Investors See Opportunity in Huge Global Demand for Lithium (Ad)
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Look at Honeywell for a Steady and Diversified Stock
Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium (Ad)
NASDAQ:ESPR

Esperion Therapeutics - ESPR Stock Forecast, Price & News

$6.64
+0.23 (+3.59%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.40
$6.64
50-Day Range
$4.92
$6.99
52-Week Range
$3.28
$14.78
Volume
778,788 shs
Average Volume
746,152 shs
Market Capitalization
$441.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.90

Esperion Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
199.7% Upside
$19.90 Price Target
Short Interest
Bearish
18.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.76
Upright™ Environmental Score
News Sentiment
0.89mentions of Esperion Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Balanced
Insiders Both Buying and Selling
Proj. Earnings Growth
Growing
From ($3.79) to ($1.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

856th out of 1,112 stocks

Pharmaceutical Preparations Industry

429th out of 544 stocks

ESPR stock logo

About Esperion Therapeutics (NASDAQ:ESPR) Stock

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics Stock Up 3.6 %

Shares of ESPR Stock opened at $6.64 on Friday. The business's fifty day moving average price is $6.15 and its 200 day moving average price is $5.36. Esperion Therapeutics has a 1-year low of $3.28 and a 1-year high of $14.78.

Esperion Therapeutics (NASDAQ:ESPR - Get Rating) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.10). The firm had revenue of $18.80 million for the quarter, compared to analyst estimates of $18.62 million. During the same quarter in the previous year, the company earned ($1.67) EPS. Esperion Therapeutics's revenue was down 53.8% on a year-over-year basis. As a group, equities research analysts anticipate that Esperion Therapeutics will post -3.79 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. upgraded Esperion Therapeutics from an "underweight" rating to a "neutral" rating and set a $6.00 target price on the stock in a research report on Wednesday, May 4th. Cowen reduced their target price on Esperion Therapeutics to $13.00 in a research note on Tuesday. Credit Suisse Group lowered shares of Esperion Therapeutics from a "neutral" rating to an "underperform" rating and cut their price target for the stock from $7.00 to $6.00 in a report on Wednesday, August 3rd. Finally, Morgan Stanley increased their price objective on shares of Esperion Therapeutics from $5.00 to $7.00 and gave the company an "underweight" rating in a report on Friday, July 15th. Four investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics has a consensus rating of "Hold" and a consensus price target of $19.90.

Insider Activity at Esperion Therapeutics

In other Esperion Therapeutics news, CEO Sheldon L. Koenig purchased 8,606 shares of Esperion Therapeutics stock in a transaction on Friday, August 5th. The shares were purchased at an average cost of $5.80 per share, with a total value of $49,914.80. Following the completion of the transaction, the chief executive officer now directly owns 198,771 shares in the company, valued at approximately $1,152,871.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Joanne M. Foody sold 3,901 shares of the business's stock in a transaction dated Tuesday, July 19th. The stock was sold at an average price of $6.55, for a total value of $25,551.55. Following the completion of the sale, the insider now directly owns 109,077 shares of the company's stock, valued at $714,454.35. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sheldon L. Koenig purchased 8,606 shares of Esperion Therapeutics stock in a transaction dated Friday, August 5th. The stock was acquired at an average price of $5.80 per share, for a total transaction of $49,914.80. Following the completion of the transaction, the chief executive officer now owns 198,771 shares in the company, valued at approximately $1,152,871.80. The disclosure for this purchase can be found here. Over the last three months, insiders sold 8,905 shares of company stock worth $50,693. 2.40% of the stock is owned by company insiders.

Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Stock News Headlines

Esperion Therapeutics Tops Q1 EPS by 11c
See More Headlines
Receive ESPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ESPR Company Calendar

Last Earnings
8/02/2022
Today
8/12/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ESPR
Fax
N/A
Employees
218
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.90
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+199.7%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$-269,110,000.00
Net Margins
-381.64%
Pretax Margin
-381.64%

Debt

Sales & Book Value

Annual Sales
$78.45 million
Book Value
($4.38) per share

Miscellaneous

Free Float
64,955,000
Market Cap
$441.89 million
Optionable
Optionable
Beta
0.28

Key Executives

  • Mr. Sheldon L. Koenig (Age 56)
    Pres, CEO & Director
    Comp: $728.91k
  • Dr. Joanne Micale Foody FACC (Age 57)
    M.D., Chief Medical Officer
    Comp: $471.86k
  • Dr. Kenneth J. Fiorelli
    Chief Technical Operations Officer
  • Mr. Benjamin Church
    Head of Corp. Communications & Investor Relations
  • Mr. Benjamin O. Looker (Age 40)
    Gen. Counsel & Corp. Sec.
  • Mr. Keith F. Lenden (Age 49)
    VP of Corp. Devel. & Strategy
  • Ms. Betty Jean Swartz
    Chief Strategy Officer
  • Mr. Eric J. Warren R.Ph. (Age 49)
    Chief Commercial Officer
  • Ms. April Seiler
    Sr. Director of Project Management
  • Roberta Peterson
    Sr. Director of National Accounts













ESPR Stock - Frequently Asked Questions

Should I buy or sell Esperion Therapeutics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View ESPR analyst ratings
or view top-rated stocks.

What is Esperion Therapeutics' stock price forecast for 2022?

8 brokerages have issued 1 year price targets for Esperion Therapeutics' shares. Their ESPR share price forecasts range from $5.00 to $90.00. On average, they predict the company's stock price to reach $19.90 in the next twelve months. This suggests a possible upside of 199.7% from the stock's current price.
View analysts price targets for ESPR
or view top-rated stocks among Wall Street analysts.

How have ESPR shares performed in 2022?

Esperion Therapeutics' stock was trading at $5.00 at the beginning of 2022. Since then, ESPR stock has increased by 32.8% and is now trading at $6.64.
View the best growth stocks for 2022 here
.

When is Esperion Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our ESPR earnings forecast
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings data on Tuesday, August, 2nd. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.10. The biopharmaceutical company earned $18.80 million during the quarter, compared to analyst estimates of $18.62 million. The business's revenue was down 53.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.67) earnings per share.

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Platinum Investment Management Ltd. (2.44%), JPMorgan Chase & Co. (1.32%), Pinnacle Associates Ltd. (0.41%), Monaco Asset Management SAM (0.27%), Rhumbline Advisers (0.11%) and SG Americas Securities LLC (0.10%). Insiders that own company stock include Eric Warren, Joanne M Foody, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends
.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $6.64.

How much money does Esperion Therapeutics make?

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $441.91 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269,110,000.00 in net income (profit) each year or ($6.37) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

The company employs 218 workers across the globe.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.

This page (NASDAQ:ESPR) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.